About
Zysis is a privately-owned pharmaceutical company optimizing therapies for disorders of the Central Nervous System to improve sufferers’ lives.
Zysis is currently developing two new treatments. One is a once-daily, effective formulation for the treatment of speciality Anxiety disorders such as Panic Disorders and Post-Traumatic Stress Disorder.
Zysis’ other product is a once-weekly, oral tablet for the treatment of Psychotic conditions or an adjunctive treatment for Major Depressive Disorder.
Once-Weekly, Oral, Second Generation Antipsychotic
The Psychoses remain an area of high unmet need – Schizophrenia, Schizoaffective Disorder and Bipolar Disorders are difficult to diagnose and to treat effectively. One of the main issues is achieving high levels of compliance or treatment adherence amongst patients.
Any treatment that helps patients comply with therapy and therefore remain symptom-free is attractive to clinicians, carers and sufferers.
Zysis has reformulated an effective anti-psychotic compound to make it a controlled release, once-weekly, oral maintenance phase therapy. This improvement in dosing convenience could make a real different to many patients’ lives.
Once-Daily, Effective Treatment for Specialty Anxiety Conditions
Anxiety conditions can be present in up to 7% of the population. Therapies that have an indication for any anxiety disorder remain few. Zysis sees the specialty Anxiety Disorders of Panic Disorder and Post Traumatic Stress Disorder as areas of high unmet medical need.
Zysis has taken a molecule with an excellent efficacy profile and reformulated it through novel controlled-release technology to create a product with a reduced side effect profile, improved compliance and therefore better real-world effectiveness. We believe that this product would be ideally suited to be re-launched as an anxiolytic product.
Zysis is substantially funded by Catapult Venture Managers.
